Avalo Therapeutics Future Growth

Future criteria checks 0/6

Avalo Therapeutics's revenue and earnings are forecast to decline at 85.7% and 8.8% per annum respectively while EPS is expected to grow by 80.9% per annum.

Key information

-8.8%

Earnings growth rate

80.9%

EPS growth rate

Biotechs earnings growth	31.8%
Revenue growth rate	-85.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	16 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:C6K0 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-39	N/A	N/A	1
12/31/2025	N/A	-36	N/A	N/A	1
12/31/2024	N/A	-33	N/A	N/A	1
12/31/2023	2	-32	-31	-31	N/A
9/30/2023	2	-33	-32	-32	N/A
6/30/2023	17	-25	-19	-19	N/A
3/31/2023	17	-30	-21	-21	N/A
12/31/2022	18	-42	-27	-27	N/A
9/30/2022	17	-51	-40	-40	N/A
6/30/2022	4	-72	-62	-62	N/A
3/31/2022	6	-76	-69	-69	N/A
12/31/2021	5	-84	-71	-71	N/A
9/30/2021	7	-81	-68	-68	N/A
6/30/2021	6	-77	-64	-64	N/A
3/31/2021	4	-73	-53	-53	N/A
12/31/2020	7	-64	-41	-41	N/A
9/30/2020	6	-54	-28	-28	N/A
6/30/2020	7	-44	-24	-24	N/A
3/31/2020	7	-33	-22	-22	N/A
12/31/2019	7	-16	-19	-19	N/A
9/30/2019	0	-13	-20	-19	N/A
6/30/2019	2	-35	-13	-12	N/A
3/31/2019	5	-38	-7	-6	N/A
12/31/2018	7	-37	-4	-3	N/A
9/30/2018	16	-42	-4	-4	N/A
6/30/2018	37	2	16	16	N/A
3/31/2018	32	6	14	15	N/A
12/31/2017	28	8	13	13	N/A
9/30/2017	26	13	N/A	11	N/A
6/30/2017	1	-12	N/A	-11	N/A
3/31/2017	2	-13	N/A	-13	N/A
12/31/2016	1	-16	N/A	-15	N/A
9/30/2016	1	-18	N/A	-14	N/A
6/30/2016	1	-13	N/A	-13	N/A
3/31/2016	N/A	-12	N/A	-11	N/A
12/31/2015	N/A	-10	N/A	-10	N/A
9/30/2015	N/A	3	N/A	-11	N/A
6/30/2015	N/A	-2	N/A	-16	N/A
3/31/2015	N/A	-3	N/A	-16	N/A
12/31/2014	N/A	-4	N/A	-16	N/A
9/30/2014	N/A	-17	N/A	-14	N/A
12/31/2013	N/A	-13	N/A	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: C6K0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: C6K0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: C6K0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: C6K0 is forecast to have no revenue next year.

High Growth Revenue: C6K0 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if C6K0's Return on Equity is forecast to be high in 3 years time

Avalo Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Cerecor Inc. Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

Recent updates

Avalo Therapeutics, Inc. Announces Board Appointments

Hearings Panel Grants Avalo Therapeutics an Exception from Compliance with the MVLS Rule and the Bid Price Rule and Extension of Continued Listing Until December 29, 2023

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Nasdaq Determines to Delist Securities of Avalo Therapeutics

AUG Therapeutics, LLC entered into a purchase agreement to acquire rights, title and interest in, assets relating to AVTX-800 Series from Avalo Therapeutics, Inc. (NasdaqCM:AVTX).

Avalo Therapeutics, Inc. Receives Notice from Nasdaq Regarding Bid Price Rule

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$1.38 loss in 2Q 2022)

New minor risk - Insider selling

New major risk - Revenue and earnings growth

Avalo Announces Topline Data from Phase 2 Peak Trial for Avtx-002 (Quisovalimab) in Patients with Non-Eosinophilic Asthma

Insider recently bought €52k worth of stock

Insider recently bought €83k worth of stock

Insider recently bought €63k worth of stock

First quarter 2023 earnings released: US$0.85 loss per share (vs US$2.35 loss in 1Q 2022)

Insider recently bought €49k worth of stock

Insider recently bought €131k worth of stock

Full year 2022 earnings released

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. Completes Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

High number of new and inexperienced directors

Forecast to breakeven in 2024

Third quarter 2022 earnings released: EPS: US$0.34 (vs US$2.04 loss in 3Q 2021)

High number of new and inexperienced directors

Avalo Therapeutics, Inc. Advances B and T Lymphocyte Attenuator Agonist Fusion Protein (AVTX-008) to IND-Enabling Stage

Avalo Therapeutics Announces Board Changes

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Avalo Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.32 loss in 1Q 2021)

Avalo Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Avalo Therapeutics, Inc. Announces Executive and Board Changes

Avalo Therapeutics, Inc. Announces Chief Executive Officer Changes

Avalo Therapeutics, Inc. Announces Resignation of H. Jeffrey Wilkins as Chief Medical Officer

Avalo Therapeutics, Inc. Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2020)

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million.

Avalo Therapeutics, Inc.(NasdaqCM:AVTX) dropped from NASDAQ Composite Index

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.19 loss in 2Q 2020)

High number of new directors

Cerecor Inc. announced that it expects to receive $35 million in funding from Horizon Technology Finance Management, LLC

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.36 loss in 1Q 2020)

Forecast to breakeven in 2024

U.S. Food and Drug Administration Grants Fast Track Designation to CERC-002 of Cerecor Inc. for Treatment of Hospitalized Patients with COVID-19

Cerecor Inc. Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

Full year 2020 earnings released: US$0.88 loss per share (vs US$0.28 loss in FY 2019)

Revenue beats expectations

Cerecor Inc. Announces Final Efficacy Data Including 60-Day Mortality from Their Recently Completed Us-Based, Multi-Center (10 Sites)

Cerecor Inc. Appoints Schond L. Greenway as Chief Financial Officer

New 90-day high: €3.56

New 90-day high: €3.16

Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II

New 90-day high: €2.72

Cerecor Inc. Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS

New 90-day high: €2.26

Cerecor Inc. Announces First Patient Dosed in A Phase 1B Clinical Trial of Cerc-007 for the Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Inc. Enters into an Amendment to Its Existing License and Supply Agreement with Watson Laboratories, Inc

Cerecor Inc. Appoints Gilla Kaplan, to Its Board of Directors

Cerecor Inc. Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies